Odonate Therapeutics Announces Pricing of Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (the Company or Odonate), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $24.00 per share for aggregate gross proceeds of approximately $150 million. All of the shares of common stock are being offered by Odonate. In addition, Odonate has granted the underwriters a 30-day option to purchase up to 937,500 additional shares of its common stock at the initial public offering price, less the underwriting discount. The shares are expected to begin trading on the NASDAQ Global Select Market on December 7, 2017 under the ticker symbol “ODT.” The offering is expected to close on December 11, 2017, subject to customary closing conditions.

Goldman Sachs & Co. LLC and Jefferies are acting as joint book-running managers for the offering. Cowen is also acting as a bookrunner for the offering.

A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission (SEC) on December 6, 2017. This offering is being made only by means of a prospectus, copies of which may be obtained from Goldman Sachs & Co. LLC (Attention Prospectus Department, 200 West Street, New York, NY 10282; telephone: [phone]); Jefferies LLC (Attention Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022; telephone: [phone]); or Cowen and Company, LLC (c/o Broadridge Financial Services, Attention Prospectus Department, 1155 Long Island Avenue, Edgewood, NY, 11717; telephone: [phone]).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. The Company’s initial focus is on the development of tesetaxel, a novel, orally administered chemotherapy agent belonging to the taxane class. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

Contacts

Odonate Therapeutics, Inc.
John G. Lemkey, 858-731-8180
Chief Financial Officer
[e-mail]